p53 at the crossroads of MPN treatment

Isabelle Plo1

  • 1INSERM, UNITÉ MIXTE DE RECHERCHE 1009.

Blood
|August 2, 2014
PubMed

Insights

This study shows that combining an MDM2 antagonist (RG7112) with pegylated interferon α (Peg-IFNα 2a) effectively targets cancer stem cells. This combination therapy offers a new treatment strategy for myeloproliferative neoplasms (MPNs).

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Myeloproliferative neoplasms (MPNs) are a group of blood cancers.
  • The JAK2V617F mutation is a common driver in MPNs.
  • Targeting hematopoietic stem cells is crucial for effective MPN treatment.

Purpose of the Study:

  • To investigate the synergistic effects of an MDM2 antagonist and Peg-IFNα 2a in targeting JAK2V617F+ cells.
  • To provide a rationale for combination therapy in MPNs.

Main Methods:

  • Utilized an orally bioavailable MDM2 antagonist (RG7112).
  • Administered pegylated interferon α (Peg-IFNα 2a).
  • Focused on targeting JAK2V617F hematopoietic progenitors and stem cells.

Main Results:

  • Demonstrated cooperation between RG7112 and Peg-IFNα 2a.
  • Showed effective targeting of JAK2V617F hematopoietic stem cells.
  • Established a potential therapeutic strategy for MPNs.

Conclusions:

  • Combination therapy with an MDM2 antagonist and Peg-IFNα 2a is a promising approach for MPNs.
  • This strategy targets key cells driving MPN.
  • Further clinical investigation is warranted.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
8.5K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
2.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.6K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
32.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K